Skip to content
  • About
  • Contact
  • Contribute
  • Book
  • Careers
  • Podcast
  • Recommended
  • Speaking
  • All
  • Physician
  • Practice
  • Policy
  • Finance
  • Conditions
  • .edu
  • Patient
  • Meds
  • Tech
  • Social
  • Video
    • All
    • Physician
    • Practice
    • Policy
    • Finance
    • Conditions
    • .edu
    • Patient
    • Meds
    • Tech
    • Social
    • Video
    • About
    • Contact
    • Contribute
    • Book
    • Careers
    • Podcast
    • Recommended
    • Speaking

Why clinical decision making in psychiatry is difficult

Julia Frank, MD
Meds
October 17, 2012
Share
Tweet
Share

“All psychiatrists do is push drugs!”

I have heard this repeatedly, from students, wary patients, even family members who don’t pick up on a carefully worded hint that they just might benefit from getting help.  For some reason, no one makes the same complaint about infectious disease specialists, or oncologists, though I wager that the success rates of our drug treatments are roughly equivalent.

As a psychiatrist, I try to treat people with diseases, not diseases that happen to occur in people, but combining drugs with other modes of therapy requires a daily, even hourly balancing act. Add the effects of pharmaceutical marketing, especially direct to consumer advertising (followed by direct potential litigant recruitment)–some days I don’t want to get out of bed.

Beyond a general temptation to rely on drugs as the primary mode of treatment, psychiatrists feel particularly pressed to use the newest, most expensive drug. Many psychiatric patients receive their care in publicly funded clinics, under excruciatingly tight budgets. Having free samples to distribute allows us to provide a few patients with high end drugs. Clinical decision making in psychiatry is difficult because of our lack of objective measures of response. Newer psychotropic medicines do sometimes work where older ones have failed. The side effects of newer medications typically differ from those of older ones, though the overall burden of adverse consequences is arguably the same. These background forces are invisible. In the clinical moment, the selection of a particular remedy is often based more on nonmedical influences—the patient’s response to advertising, the clinic’s necessary concern with costs—than upon the prescribing professional’s careful assessment and detailed discussion with a patient.

Aggressive pharmaceutical marketing has exacerbated the problem of responsible prescribing. All of us who have visited a drug company exhibit at an annual meeting or attended a company sponsored lunch know that these activities sometimes do provide valuable information. However, the “research agenda” of many pharmaceutical and device manufacturers has shifted from developing or improving their products to research meant to increase market share. A careful 2008 study showed that $.24 of every  dollar spent by industry goes to promotion, while $.13 goes for actual research. This knowledge has made me far more wary of accepting company disseminated information.  Direct to consumer advertising has increased the pressure I feel to prescribe brand name over generic medications, new over old.

Although radical reform is still a long way off, section 6002 of the Patient Protection Affordable Care Act requires manufacturers of drugs, devices, supplies and biological materials that are covered under various federal health programs to disclose on an annual basis the payments (of various kinds) they have made to physicians and teaching hospitals.  Some details of how this regulation will be implemented are still being reviewed to ensure that the burden of resolving disputes falls on the manufacturers rather than upon individual physicians and hospitals. Section 3507 sets new standards for drug labeling, to make risk/benefit information easier to understand. These regulations will reshape, though not obliterate, the efforts of manufacturers to influence patients to demand and medical practitioners and institutions to use their  products.

Alone, these elements of the PPACA take only small steps towards redressing the balance between commerce and medical practice.  Making physicians and their patients more aware of the current tactics of the big pharmaceutical firms may simply prompt these firms to develop newer, unregulated marketing strategies—in the real world, this could mean even more direct to consumer advertising. Other provisions of the act potentially foster more substantial, long term reform. Strong federal support for basic and comparative effectiveness research may do much to bring real effectiveness, and efficiency, into the marketplace.  And finally, the law includes tax credits to encourage pharmaceutical firms to rededicate themselves to developing drugs that genuinely improve upon what is available—the best marketing strategy of all.

Julia Frank is a psychiatrist who blogs at Progress Notes.

Prev

AMA: Prescription for the future of medicine

October 17, 2012 Kevin 4
…
Next

Some patients need absolution, not medicine

October 17, 2012 Kevin 11
…

Tagged as: Medications, Psychiatry, Public Health & Policy

Post navigation

< Previous Post
AMA: Prescription for the future of medicine
Next Post >
Some patients need absolution, not medicine

ADVERTISEMENT

More by Julia Frank, MD

  • a desk with keyboard and ipad with the kevinmd logo

    Unregulated gun access and its drain on medical resources

    Julia Frank, MD
  • a desk with keyboard and ipad with the kevinmd logo

    The stigma experienced by patients with psychiatric disorders

    Julia Frank, MD
  • a desk with keyboard and ipad with the kevinmd logo

    Should medical students consider a combined psychiatry residency?

    Julia Frank, MD

More in Meds

  • A psychiatrist’s 20-year journey with ketamine

    Muhamad Aly Rifai, MD
  • How drug companies profit by inventing diseases

    Martha Rosenberg
  • Every medication error is a system failure, not a personal flaw

    Muhammad Abdullah Khan
  • Why kratom addiction is the next public health crisis

    Muhamad Aly Rifai, MD
  • FDA delays could end vital treatment for rare disease patients

    GJ van Londen, MD
  • Pharmacists are key to expanding Medicaid access to digital therapeutics

    Amanda Matter
  • Most Popular

  • Past Week

    • Why your clinic waiting room may affect patient outcomes

      Ziya Altug, PT, DPT and Shirish Sachdeva, PT, DPT | Conditions
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • Why transplant equity requires more than access

      Zamra Amjid, DHSc, MHA | Policy
    • The ethical crossroads of medicine and legislation

      M. Bennet Broner, PhD | Conditions
    • How robotics are transforming the next generation of vascular care [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • How robotics are transforming the next generation of vascular care [PODCAST]

      The Podcast by KevinMD | Podcast
    • The high cost of gender inequity in medicine

      Kolleen Dougherty, MD | Physician
    • Mpox isn’t over: A silent epidemic is growing

      Melvin Sanicas, MD | Conditions
    • How your family system secretly shapes your health

      Su Yeong Kim, PhD | Conditions
    • Women physicians: How can they survive and thrive in academic medicine?

      Elina Maymind, MD | Physician
    • The human case for preserving the nipple after mastectomy

      Thomas Amburn, MD | Conditions

Subscribe to KevinMD and never miss a story!

Get free updates delivered free to your inbox.


Find jobs at
Careers by KevinMD.com

Search thousands of physician, PA, NP, and CRNA jobs now.

Learn more

View 2 Comments >

Founded in 2004 by Kevin Pho, MD, KevinMD.com is the web’s leading platform where physicians, advanced practitioners, nurses, medical students, and patients share their insight and tell their stories.

Social

  • Like on Facebook
  • Follow on Twitter
  • Connect on Linkedin
  • Subscribe on Youtube
  • Instagram

ADVERTISEMENT

ADVERTISEMENT

  • Most Popular

  • Past Week

    • Why your clinic waiting room may affect patient outcomes

      Ziya Altug, PT, DPT and Shirish Sachdeva, PT, DPT | Conditions
    • Nuclear verdicts and rising costs: How inflation is reshaping medical malpractice claims

      Robert E. White, Jr. & The Doctors Company | Policy
    • How new loan caps could destroy diversity in medical education

      Caleb Andrus-Gazyeva | Policy
    • Why transplant equity requires more than access

      Zamra Amjid, DHSc, MHA | Policy
    • The ethical crossroads of medicine and legislation

      M. Bennet Broner, PhD | Conditions
    • How robotics are transforming the next generation of vascular care [PODCAST]

      The Podcast by KevinMD | Podcast
  • Past 6 Months

    • Health equity in Inland Southern California requires urgent action

      Vishruth Nagam | Policy
    • Why transgender health care needs urgent reform and inclusive practices

      Angela Rodriguez, MD | Conditions
    • How restrictive opioid policies worsen the crisis

      Kayvan Haddadan, MD | Physician
    • New student loan caps could shut low-income students out of medicine

      Tom Phan, MD | Physician
    • Why pain doctors face unfair scrutiny and harsh penalties in California

      Kayvan Haddadan, MD | Physician
    • mRNA post vaccination syndrome: Is it real?

      Harry Oken, MD | Conditions
  • Recent Posts

    • How robotics are transforming the next generation of vascular care [PODCAST]

      The Podcast by KevinMD | Podcast
    • The high cost of gender inequity in medicine

      Kolleen Dougherty, MD | Physician
    • Mpox isn’t over: A silent epidemic is growing

      Melvin Sanicas, MD | Conditions
    • How your family system secretly shapes your health

      Su Yeong Kim, PhD | Conditions
    • Women physicians: How can they survive and thrive in academic medicine?

      Elina Maymind, MD | Physician
    • The human case for preserving the nipple after mastectomy

      Thomas Amburn, MD | Conditions

MedPage Today Professional

An Everyday Health Property Medpage Today
  • Terms of Use | Disclaimer
  • Privacy Policy
  • DMCA Policy
All Content © KevinMD, LLC
Site by Outthink Group

Why clinical decision making in psychiatry is difficult
2 comments

Comments are moderated before they are published. Please read the comment policy.

Loading Comments...